Sofinnova Venture Partners X, L.P. - Aug 11, 2022 Form 4 Insider Report for CinCor Pharma, Inc. (CINC)

Role: 10%+ Owner
Signature: Sofinnova Venture Partners X, L.P., By /s/ Nathalie Auber, Attorney-in-Fact
Stock symbol: CINC
Transactions as of: Aug 11, 2022
Transactions value $: $15,000,000
Form type: 4
Date filed: 8/15/2022, 03:46 PM
Previous filing: Feb 14, 2022
Next filing: Feb 8, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CINC	Common Stock	Purchase	$15M	+500K	+8.97%	$30.00	6.07M	Aug 11, 2022	By Sofinnova Venture Partners X, L.P.	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares are directly held by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X") is the general partner of SVP X. Dr. James I. Healy and Dr. Maha Katabi are managing members of SM X and may be deemed to share voting and dispositive power over the shares held by SVP X. Each of SM X and Dr. Katabi disclaims beneficial ownership of such shares except to the extent of its or her respective pecuniary interest therein. Dr. Healy is a director of the Issuer and files separate Section 16 reports.

Content

The shares are directly held by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X") is the general partner of SVP X. Dr. James I. Healy and Dr. Maha Katabi are managing members of SM X and may be deemed to share voting and dispositive power over the shares held by SVP X. Each of SM X and Dr. Katabi disclaims beneficial ownership of such shares except to the extent of its or her respective pecuniary interest therein. Dr. Healy is a director of the Issuer and files separate Section 16 reports.